Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models

被引:37
作者
Furugohri, T [1 ]
Shiozaki, Y [1 ]
Muramatsu, S [1 ]
Honda, Y [1 ]
Matsumoto, C [1 ]
Isobe, K [1 ]
Sugiyama, N [1 ]
机构
[1] Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, New Prod Res Labs 2, Edogawa Ku, Tokyo 1348630, Japan
关键词
disseminated intravascular coagulation model; venous thrombosis model; factor Xa inhibitor; thrombin inhibitor; protein C; thrombin generation;
D O I
10.1016/j.ejphar.2005.03.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We compared the antithrombotic properties of a factor Xa inhibitor (DX-9065a) with those of a thrombin inhibitor (melagatran) in a rat disseminated intravascular coagulation model and a rat venous thrombosis model. Rat disseminated intravascular coagulation and venous thrombosis models were produced by injection of tissue factor and platinum wire placement, respectively. DX-9065a exerted antithrombotic effects dose dependently in both models. Melagatran was also effective in the venous thrombosis model, whereas it showed an aggravation in the disseminated intravascular coagulation model at low but not high doses. In the in vitro study, DX-9065a decreased the C-max of the thrombin generation curve in plasma irrespective of whether protein C was present or not. However, melagatran increased the C-max at low concentrations when protein C was present. This increase was not detected in protein C-deficient plasma. These results suggest that, unlike DX-9065a, melagatran in low doses aggravates disseminated intravascular coagulation by increasing thrombin generation, which may be partly due to suppression of negative feedback by activated protein C. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 33 条
[1]  
Bata I, 1997, CIRCULATION, V96, P769
[2]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[3]   Heparin-induced thrombocytopenia [J].
Chong, BH .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (07) :1471-1478
[4]   Molecular recognition in the protein C anticoagulant pathway [J].
Dahlbäck, B ;
Villoutreix, BO .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (07) :1525-1534
[5]  
Eriksson BI, 1997, THROMB HAEMOSTASIS, V78, P1404
[6]   Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs [J].
Eriksson, M ;
Saldeen, T ;
Mattsson, C ;
Larsson, A .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2000, 44 (01) :24-31
[7]  
Eriksson M, 1998, THROMB HAEMOSTASIS, V80, P1022
[8]   Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans [J].
Eriksson, UG ;
Bredberg, U ;
Hoffmann, KJ ;
Thuresson, A ;
Gabrielsson, M ;
Ericsson, H ;
Ahnoff, M ;
Gislén, K ;
Fager, G ;
Gustafsson, D .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :294-305
[9]   Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation [J].
Esmon, CT .
CRITICAL CARE MEDICINE, 2001, 29 (07) :S48-S51
[10]   BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis - Comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban [J].
Finkle, CD ;
St Pierre, A ;
Leblond, L ;
Deschenes, I ;
DiMaio, J ;
Winocour, PD .
THROMBOSIS AND HAEMOSTASIS, 1998, 79 (02) :431-438